GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
Beyond Amyloid Plaques: How Brainshuttle Drugs, Primary Care Blood Tests, and Cellular Science Are Rewriting Alzheimer’s Trials in Late 2026
Explore the latest November 2026 Alzheimer's clinical trial updates. Learn how Roche's Brainshuttle technology crosses the blood-brain barrier, how FDA-cleared blood tests simplify diagnosis in primary care, and what five-year data reveals about slowing cognitive decline.
Unlocking the Brain: Why NeuroDiscovery Matters and Where to Learn More
Neurodiscovery, in its broadest sense, encompasses the multidisciplinary field dedicated to unraveling the mysteries of the nervous system. It’s a vibrant tapestry woven from threads of neuroscience, biology, chemistry, physics, psychology, computer science, and even engineering. This collaborative effort aims to decipher how the brain develops, functions, and changes throughout life,
The Unseen Risk: Navigating the Perilous Path of Clinical Trials
The relentless march of medical advancement is a beacon of hope for millions, a testament to humanity's unyielding desire to conquer disease and extend life. At the forefront of this crusade stands the clinical trial, the crucible in which experimental treatments are rigorously tested. While these trials are often hailed as pivotal steps toward groundbreaking therapies, it is imperative to acknowledge the stark and sometimes devastating reality: participation in clinical trials can carry life-threatening consequences. Beyond the statistics and scientific jargon
Decoding the Latest Alzheimer's Setback: Why J&J’s "Failed" Drug Trial is Actually a Hidden Victory for Brain Science
When we think about the fight against Alzheimer’s disease, we often picture a coordinated, unstoppable march toward a cure led by massive organizations like the National Institute on Aging and the Alzheimer's Association.
Optimizing FDA Diversity Action Plan Compliance and Alzheimer’s Clinical Trial Matching Through Agentic AI
Discover how Glassbury AI leverages agentic NLP, SMART on FHIR protocols, and trust-centric community frameworks to solve Alzheimer's trial enrollment bottlenecks, de-risk asset beta, and automate FDA Diversity Action Plan (DAP) compliance under FDORA.
Caregivers and Mental Health: The Unsung Heroes Need Support Too
Caregiving is an act of profound love and dedication, but it can also be a challenging journey filled with emotional, physical, and mental strain.
A Son's Reflections on Caring for His Dying Mother by Corey Hubbard
When I first became a caregiver for my terminally ill mother, I was thrust into a world I was wholly unprepared for. The woman who had always been my pillar of strength, my source of unwavering support, was now vulnerable and dependent on me.
Eliminating Bias in Pre-Screening: How Agentic AI Parses Unstructured EHR Notes for Alzheimer’s Research
Discover how Glassbury AI’s agentic architecture and zero-text FHIR mapping help biopharma sponsors achieve FDA Diversity Action Plan (DAP) compliance and eliminate Alzheimer’s trial screen failures.